Research Grants Accepting Applications NephCure-PARASOL Grant Program NephCure announces the call for applications for its scientific grant program to support the PARASOL project. PARASOL is a collaborative international effort that aims to define the quantitative relationships between short-term changes in biomarkers (proteinuria and GFR) and long-term outcomes in order to support the use of alternative proteinuria-based endpoints as a basis for accelerated and traditional approval. The PARASOL group will achieve this in 2024 by conducting a large-scale analysis of existing data from patients of all ages with FSGS who have participated in observational cohort studies, completed clinical trials, regional or national registries, or real-world data sets. Eligibility The program is open to all investigators or clinicians who oversee an existing cohort study, registry, or real-world data inclusive of substantial FSGS patient data meeting the dataset eligibility criteria defined by the PARASOL Data Analysis Team. Funding NephCure will award funds in accordance with anticipated costs per project to support high quality registries contributions to PARASOL. To protect the integrity of the PARASOL study and ensure regulatory compliance, applying registries must be reviewed and approved by the PARASOL Organizing Committee before submission of a proposal for funding from NephCure. Click here for the grant application Click here for more information NephCure-NEPTUNE Ancillary Studies Grant Program NephCure announces the next call for applications for its scientific grant program to support investigator-initiated studies that employ NEPTUNE resources to advance clinical and translational research in glomerular disease. The program is open to all scientists, whether a participant in the NEPTUNE Consortium or not. Proposed projects can include but are not limited to those that can be used to generate feasibility data to support advancement of promising future studies and projects to develop clinical assays, or protocols, or early phase clinical trials. NephCure will award up to $150,000 total cost per project after a competitive process to select the most meritorious project. To protect the integrity of the overall NEPTUNE study, prioritize the utilization of its resources for scientific advancement, ensure regulatory compliance and monitor participant burden, ancillary studies must be reviewed and approved by the NEPTUNE Ancillary Study Review Committee (ARC) and the Steering Committee (SC) before submission of a proposal for funding from NephCure. Click here for the NEPTUNE LOI Click here for more information NephCure-CureGN Pilot Project Grant Program NephCure announces the next call for applications for a research grant program to support investigator-initiated studies that employ CureGN resources to advance clinical and translational research in glomerular disease. The program is open to all scientists, including those within and outside of the CureGN Consortium. Proposed projects are limited to those that can be used to generate feasibility data to support additional research aimed toward advancing diagnosis, treatment or cure of human glomerular disease. NephCure will provide funding of up to $100,000 direct cost for one project after a competitive process to select the most meritorious projects. Click here for the CureGN LOI Click here for more information NOTE: In any one calendar year, applicants can apply for funding to either the NephCure-NEPTUNE or NephCure-CureGN program but cannot apply to both programs simultaneously. Opportunities Outside of NephCure National Institutes of Health Grants for Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes The NIH has released two funding opportunity announcements inviting researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiatives seek applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials. Initial application dates are Tuesday, May 17, 2022. Visit these links to learn more: R03 Small Grant Program, Clinical Trial Not Allowed R21 Exploratory/Developmental Research Grant, Clinical Trial Not Allowed